The Food and Drug Administration (FDA) has now identified the previous recall of certain FreeStyle Libre glucose monitor ...

First Alleged U.S. Death from Defective Glucose Monitors Prompts Legal Action—7 Deaths Reported Globally, 3 Million Devices Recalled ONTARIO, Calif., Feb.

Abbott Laboratories (NYSE:ABT) is one of the best 52-week low blue-chip stocks to buy right now. Reuters reported on February ...

Spotted on the Alameda calendar: Bay Area's 26th Annual Community Employment Day Career Fair ...

FDA warning letter data reveals the same top 10 compliance issues have plagued medtech for 20 years, with CAPAs leading at 12 ...

The S&P 500 has performed exceedingly well over the past two years, powering to all-time highs amid easing inflation and the ...

FDA's new medical device quality management rules align U.S. standards with global requirements and give inspectors new ...

Often, the idea of going to the doctor only crosses our minds when we're experiencing symptoms of illness. But in reality, the most powerful step you can take for your long-term health is identifying ...

The FDA has escalated the recall of specific Abbott FreeStyle Libre 3 and 3 Plus CGMs to Class I, the highest level of ...

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Abbott Laboratories (NYSE:ABT) received an FDA warning ...

Abbott received a warning letter from the Food and Drug Administration related to its FreeStyle Libre continuous glucose monitors. The warning letter, dated Jan. 23 and posted to the FDA’s website on ...